Your browser doesn't support javascript.
loading
Gain of Chromosome 5q Predicts a Favorable Prognosis in Localized Renal Cell Carcinoma.
Lebacle, Cedric; Pooli, Aydin; Shuch, Brian; Rao, Nagesh; Chamie, Karim; Kroeger, Nils; Faiena, Izak; Liu, Sandy; Wood, Erika L; Belldegrun, Arie; Drakaki, Alexandra; Pantuck, Allan J.
Affiliation
  • Lebacle C; Department of Urology, Institute of Urologic Oncology (IUO), David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
  • Pooli A; Department of Urology, University Hospital Bicetre, APHP, University Paris-Saclay, Le Kremlin Bicetre, France.
  • Shuch B; Department of Urology, Institute of Urologic Oncology (IUO), David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
  • Rao N; Department of Urology, Institute of Urologic Oncology (IUO), David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
  • Chamie K; Department of Pathology and Lab Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
  • Kroeger N; Department of Urology, Institute of Urologic Oncology (IUO), David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
  • Faiena I; Department of Urology, University Medicine Greifswald, Greifswald, Germany.
  • Liu S; Department of Urology, Institute of Urologic Oncology (IUO), David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
  • Wood EL; Department of Hematology and Oncology, David Geffen School of Medicine at University of California, Los Angeles, California, USA.
  • Belldegrun A; Department of Urology, Institute of Urologic Oncology (IUO), David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
  • Drakaki A; Department of Urology, Institute of Urologic Oncology (IUO), David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
  • Pantuck AJ; Department of Urology, Institute of Urologic Oncology (IUO), David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Cancer Invest ; 42(1): 97-103, 2024 Jan.
Article in En | MEDLINE | ID: mdl-38314786
ABSTRACT
Approximately 65% of renal cell carcinomas (RCC) are diagnosed at a localized stage. We investigated the chromosome 5q gain impact on disease-free survival (DFS) in RCC patients. Overall, 676 patients with stages 1-2 RCC and having cytogenetic analysis were included. Gain of 5q was observed in 108 patients, more frequently in clear cell (ccRCC) than non-clear cell tumors. Gain of 5q is likely an independent prognostic factor since the concerned patients had a decreased recurrence risk in stages 1-2 RCC, confirmed in multivariable analysis. Detecting 5q gain could enhance recurrence risk assessment, allowing tailored post-surgery surveillance, and reducing unnecessary treatments.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Kidney Neoplasms Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Cancer Invest Year: 2024 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Kidney Neoplasms Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Cancer Invest Year: 2024 Type: Article Affiliation country: United States